Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 27.00 GBp
Change Today 0.00 / 0.00%
Volume 6.1K
AGY On Other Exchanges
As of 11:30 AM 10/7/15 All times are local (Market data is delayed by at least 15 minutes).

allergy therapeutics plc (AGY) Snapshot

27.00 GBp
Previous Close
27.00 GBp
Day High
27.00 GBp
Day Low
27.00 GBp
52 Week High
08/4/15 - 27.75 GBp
52 Week Low
10/16/14 - 17.75 GBp
Market Cap
Average Volume 10 Days
0.0022 GBp
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

allergy therapeutics plc (AGY) Related Businessweek News

No Related Businessweek News Found

allergy therapeutics plc (AGY) Details

Allergy Therapeutics plc, a specialty pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical vaccine products for the immunological treatment of allergic conditions primarily in Europe. The company’s primary flagship product consists of the Pollinex Quattro for the treatment of allergic conditions; and monophosphoryl-lipid A, a substance, which enhances the immune response to an antigen or allergen. It offers sublingual product, including Oralvac Compact; Venomil product, which is used for the wasp and bee treatment; probiotic products, such as Kallergen-Th, ATI Prob, and Pollagen; Acarovac Plus, a novel tyrosine-adsorbed, modified-allergen product developed for treatment of perennial mite allergy; and DAP, a product for use in the diagnosis of type I or immediate hypersensitivity to benzylpenicillin and related antibiotics (betalactams) by means of cutaneous tests (prick and intradermal). The company markets its products under various brands, including Pollinex Quattro, Polligoid, and TA Gräser Top. Allergy Therapeutics plc was founded in 1934 and is headquartered in Worthing, the United Kingdom.

Founded in 1934

allergy therapeutics plc (AGY) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 291.0K GBP
Finance Director, Company Secretary and Direc...
Total Annual Compensation: 192.8K GBP
Compensation as of Fiscal Year 2014.

allergy therapeutics plc (AGY) Key Developments

Allergy Therapeutics plc Reports Consolidated Earnings Results for the Year Ended June 30, 2015

Allergy Therapeutics plc reported consolidated earnings results for the year ended June 30, 2015. For the period, the company reported revenue of £43,230,000 compared with £41,955,000 for the same period last year. Operating profit was £725,000 compared with £1,209,000 for the same period last year. Profit  before tax was £654,000 compared with £1,084,000 for the same period last year. Profit for the period was £108,000 or 0.02 pence diluted per share compared with £741,000 or 0.16 pence diluted per share for the same period last year. Net cash generated by operating activities was £2,005,000 compared with £2,173,000 for the same period last year. Payments for intangible assets was £13,000 compared with £22,000 for the same period last year. Payments for property plant and equipment was £1,091,000 compared with £898,000 for the same period last year.

Allergy Therapeutics plc Provides Revenue Guidance for the Full Year Ended June 30, 2015

Allergy Therapeutics plc provided revenue guidance for the full year ended June 30, 2015. The company expects to report revenue growth of 11% for the year at constant currency, reflecting revenues of approximately £46.6 million. This double digit growth rate in a flat market demonstrates that Allergy Therapeutics has outperformed the market, gaining market share of approximately 1% a year. These gains have occurred in all of the company's key markets, making Allergy Therapeutics the outstanding performer in Europe in this competitive area. Reported revenues are expected to be approximately £43.2 million, slightly ahead of analyst expectations, representing growth of 3%, despite the negative impact from the weakening Euro.

Allergy Therapeutics Announces Positive Results from its Prospective Observational Acarovac Plus Clinical Study

Allergy Therapeutics announced positive results from its prospective observational Acarovac Plus clinical study for the treatment of house dust mite allergy. Acarovac Plus is being developed as one of the Company's new generation of products to address the perennial allergy market with innovative and short-course therapies. At the Adjuvants in Allergy conference over the past weekend, Dr. Albert Roger, Director of the Allergy Unit at Universitari Hospital Germans Trias Pujol, Badalona Spain, presented the results of a prospective observational one-year follow-up study, comparing the safety, tolerability and long-term effectiveness of Acarovac Plus using Dermatophagoides pteronyssinus (house dust mite) in 30 adult patients with allergic rhinitis and/or asthma. Acarovac Plus has been designed to administer maintenance doses every 6-8 weeks, reducing the number of annual injections required and providing a natural, biodegradable, alternative depot vaccine. Tolerability of Acarovac Plus was demonstrated with no reported adverse events. The effectiveness of Acarovac Plus was measured in patients using a nasal provocation test, which evaluates the sensitivity of each patient to mite allergens. Nasal airway assessments were performed using peak nasal inspiratory flow measurements. In summary, a reduction in symptom scores of >50% were observed during follow up visits after one year. Immunological markers were also assessed and showed significant improvements in antibody IgG4 and anti-inflammatory IL-10 molecules, indicating tolerance induction in patients after one year of treatment. A validated patient satisfaction survey provided information that was reflective of the clinical findings from the study. A high degree of overall patient satisfaction was observed, which encompassed significant improvements in scores after one year in relation to overall effectiveness and convenience of the treatment. This reinforces one of the main objectives of Allergy Therapeutics in improving patient life by producing effective treatments, while at the same time reducing the discomfort of injections, improving compliance and adherence of allergy immunotherapy products. Further to the efficacy noted for Acarovac Plus, Allergy Therapeutics is developing Acarovac Quattro, an ultra-short course therapy utilising the adjuvant monophosphoryl lipid A (MPL), which is used in the Company's successful Pollinex Quattro product range currently in late stage development in Europe and the US.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGY:LN 27.00 GBp 0.00

AGY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AGY.
View Industry Companies

Industry Analysis


Industry Average

Valuation AGY Industry Range
Price/Earnings 100.0x
Price/Sales 3.0x
Price/Book 4.1x
Price/Cash Flow 1,315.5x
TEV/Sales 3.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALLERGY THERAPEUTICS PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at